SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Cohen Hannah)
 

Sökning: WFRF:(Cohen Hannah) > Optimal timing of a...

  • Best, Jonathan G.University College London (författare)

Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS) : Protocol for a randomized controlled trial

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-01-12
  • SAGE Publications,2022

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:f2bca6f0-7530-48c2-b76a-7185192dd5d1
  • https://lup.lub.lu.se/record/f2bca6f0-7530-48c2-b76a-7185192dd5d1URI
  • https://doi.org/10.1177/17474930211057722DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Rationale: Atrial fibrillation causes one-fifth of ischemic strokes, with a high risk of early recurrence. Although long-term anticoagulation is highly effective for stroke prevention in atrial fibrillation, initiation after stroke is usually delayed by concerns over intracranial hemorrhage risk. Direct oral anticoagulants offer a significantly lower risk of intracranial hemorrhage than other anticoagulants, potentially allowing earlier anticoagulation and prevention of recurrence, but the safety and efficacy of this approach has not been established. Aim: Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS) will investigate whether early treatment with a direct oral anticoagulant, within four days of stroke onset, is as effective or better than delayed initiation, 7 to 14 days from onset, in atrial fibrillation patients with acute ischemic stroke. Methods and design: OPTIMAS is a multicenter randomized controlled trial with blinded outcome adjudication. Participants with acute ischemic stroke and atrial fibrillation eligible for anticoagulation with a direct oral anticoagulant are randomized 1:1 to early or delayed initiation. As of December 2021, 88 centers in the United Kingdom have opened. Study outcomes: The primary outcome is a composite of recurrent stroke (ischemic stroke or symptomatic intracranial hemorrhage) and systemic arterial embolism within 90 days. Secondary outcomes include major bleeding, functional status, anticoagulant adherence, quality of life, health and social care resource use, and length of hospital stay. Sample size target: A total of 3478 participants assuming event rates of 11.5% in the control arm and 8% in the intervention arm, 90% power and 5% alpha. We will follow a non-inferiority gatekeeper analysis approach with a non-inferiority margin of 2 percentage points. Discussion: OPTIMAS aims to provide high-quality evidence on the safety and efficacy of early direct oral anticoagulant initiation after atrial fibrillation-associated ischemic stroke. Trial registrations: ISRCTN: 17896007; ClinicalTrials.gov: NCT03759938

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Arram, LizUniversity College London (författare)
  • Ahmed, NorinUniversity College London (författare)
  • Balogun, MaryamUniversity College London (författare)
  • Bennett, KateUniversity College London (författare)
  • Bordea, EkaterinaUniversity College London (författare)
  • Campos, Marta G.University College London (författare)
  • Caverly, EmiliaUniversity College London (författare)
  • Chau, MarisaUniversity College London (författare)
  • Cohen, HannahUCL Cancer Institute (författare)
  • Dehbi, Hakim MoulayUniversity College London (författare)
  • Doré, Caroline J.University College London (författare)
  • Engelter, Stefan T.University of Basel (författare)
  • Fenner, RobertUniversity College London (författare)
  • Freemantle, NickUniversity College London (författare)
  • Hunter, RachaelUniversity College London (författare)
  • James, MartinUniversity of Exeter (författare)
  • Lip, Gregory Y.H.Aalborg University,University of Liverpool (författare)
  • Murray, Macey L.University College London (författare)
  • Norrving, BoLund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Klinisk strokeforskning,Forskargrupper vid Lunds universitet,Stroke policy och kvalitetsregisterforskning,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Clinical Stroke Research Group,Lund University Research Groups,Stroke policy and quality register research,Skåne University Hospital(Swepub:lu)neur-bno (författare)
  • Sprigg, NikolaQueen's Medical Centre, Nottingham (författare)
  • Veltkamp, RolandImperial College London,Alfried Krupp Krankenhaus (författare)
  • Zaczyk, IwonaUniversity College London (författare)
  • Werring, David J.University College London (författare)
  • University College LondonUCL Cancer Institute (creator_code:org_t)
  • the OPTIMAS investigators

Sammanhörande titlar

  • Ingår i:International Journal of Stroke: SAGE Publications17:5, s. 583-5891747-49301747-4949

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy